



COPY OF PAPERS
ORIGINALLY FILED

GENENT.33CP2C2

RECEIVED

MAR 6 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Presta *et al.*

Appl. No. : 09/724,524

Filed : November 27, 2000

For : HUMAN TRK RECEPTORS
AND NEUROTROPHIC
FACTOR INHIBITORS

Examiner : Davis, Minh Tam B.

) Group Art Unit: 1642

) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first class mail in
) an envelope addressed to: Commissioner of
) Patents, United States Patent and Trademark
) Office, P.O. Box 2327, Arlington, VA 22202, on

) February 1, 2002

) (Date)

) 
) Ginger R. Dreger, Reg. No. 33,055

AMENDMENT AND RESPONSE TO ELECTION/RESTRICTION REQUIREMENT

Commissioner of Patents
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

In Response to the Office Action mailed on December 4, 2001 (Paper No. 6) in connection with the above-identified patent application, please amend this application as follows. A request for a one-month extension-of-time and the appropriate fee, in accordance with 37 C.F.R. § 1.136(a), are also provided.

IN THE CLAIMS:

Please cancel claims 1-5, without prejudice.

Please enter new claims 6-19 as follows:

C1
B1
6. (New) A method for the diagnosis of a pathological condition characterized by the over-expression or under-expression of a neurotrophin receptor selected from human TrkA, human TrkB and human TrkC in a subject, comprising

02/26/2002 SDENB001 00000068 09724524

01 FC:102

84.00 GP